Approval · Notice of Compliance 32821 · 2024
LENVIMA: Notice of Compliance 32821
Issued March 6, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32821
- Date
- March 6, 2024
- Company
- Eisai LimitedWoodcliff Lake, New Jersey, United States
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Alternate Drug Substance manufacturing, packaging, release and stability testing site.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LENVIMA | Not yet assigned | — |
Medicinal ingredients
- LENVATINIB MESYLATE 4 MG per DOSE
- LENVATINIB MESYLATE 10 MG per DOSE
- LENVATINIB MESYLATE 8 MG per DOSE
- LENVATINIB MESYLATE 12 MG per DOSE
- LENVATINIB MESYLATE 14 MG per DOSE
- LENVATINIB MESYLATE 18 MG per DOSE
- LENVATINIB MESYLATE 20 MG per DOSE
- LENVATINIB MESYLATE 24 MG per DOSE